Fetal bovine serum requirement for pyrrolidine dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor cells

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 135-139

  Oh, Da Hee ^a   Bang, Jun Soo ^a   Choi, Hyun Mi ^a   Yang, Hyung In ^a   Yoo, Myung Chul ^a   Kim, Kyoung Soo ^a  

^a Kyung Hee University College of Medicine   (South Korea)

Author keywords

Clioquinol; PDTC (Pyrrolidine dithiocarbamate); Proteasome inhibitor; TPEN

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CLIOQUINOL; FENOFIBRATE; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; PYRROLIDINE DITHIOCARBAMATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CULTURE OPTIMIZATION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD PROTEINS; BREAST NEOPLASMS; CATTLE; CELL LINE, TUMOR; CELL SURVIVAL; CHELATING AGENTS; CULTURE MEDIA; DIALYSIS; ENZYME INHIBITORS; FEMALE; FETAL BLOOD; HUMANS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLIDINES; SERUM; THIOCARBAMATES; ZINC;

EID: 78049278346     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.048     Document Type: Article

References (50)

1. Ahtoniemi T., Goldsteins G., Keksa-Goldsteine V., Malm T., Kanninen K., Salminen A., Koistinaho J. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol. Pharmacol. 2007, 71:30-37.
2. Bessho R., Matsubara K., Kubota M., Kuwakado K., Hirota H., Wakazono Y., Lin Y.W., Okuda A., Kawai M., Nishikomori R., et al. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappa B (NF-kappa B) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem. Pharmacol. 1994, 48:1883-1889.
3. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 1999, 6:436-458.
4. Brennan P., O'Neill L.A. 2-mercaptoethanol restores the ability of nuclear factor kappa B (NF kappa B) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF kappa B by PDTC. Biochem. J. 1996, 320(Pt 3):975-981.
5. Brewer G.J. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp. Biol. Med. (Maywood) 2001, 226:665-673.
6. Brewer G.J., Dick R.D., Grover D.K., LeClaire V., Tseng M., Wicha M., Pienta K., Redman B.G., Jahan T., Sondak V.K., Strawderman M., LeCarpentier G., Merajver S.D. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin. Cancer Res. 2000, 6:1-10.
7. Canzoniero L.M., Manzerra P., Sheline C.T., Choi D.W. Membrane-permeant chelators can attenuate Zn2+-induced cortical neuronal death. Neuropharmacology 2003, 45:420-428.
8. Caravita T., de Fabritiis P., Palumbo A., Amadori S., Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat. Clin. Pract. 2006, 3:374-387.
9. Chen S.H., Liu S.H., Liang Y.C., Lin J.K., Lin-Shiau S.Y. Death signaling pathway induced by pyrrolidine dithiocarbamate-Cu(2+) complex in the cultured rat cortical astrocytes. Glia 2000, 31:249-261.
10. Chen D., Peng F., Cui Q.C., Daniel K.G., Orlu S., Liu J., Dou Q.P. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front. Biosci. 2005, 10:2932-2939.
11. Chen J., Du C., Kang J., Wang J. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis. Chem. Biol. Interact. 2008, 171:26-36.
12. Ciechanover A., Finley D., Varshavsky A. Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell 1984, 37:57-66.
13. Daniel K.G., Harbach R.H., Guida W.C., Dou Q.P. Copper storage diseases: Menkes, Wilsons, and cancer. Front. Biosci. 2004, 9:2652-2662.
14. Daniel K.G., Chen D., Orlu S., Cui Q.C., Miller F.R., Dou Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res. 2005, 7:R897-R908.
15. Ding W.Q., Yu H.J., Lind S.E. Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett. 2008, 271:251-259.
16. Dutcher J.P. Angiogenesis and melanoma. Curr. Oncol. Rep. 2001, 3:353-358.
17. Eatock M.M., Schatzlein A., Kaye S.B. Tumour vasculature as a target for anticancer therapy. Cancer Treat. Rev. 2000, 26:191-204.
18. Fox S.B., Gasparini G., Harris A.L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2001, 2:278-289.
19. Gourley M., Williamson J.S. Angiogenesis: new targets for the development of anticancer chemotherapies. Curr. Pharm. Des. 2000, 6:417-439.
20. Hagar H.H., El-Medany A., El-Eter E., Arafa M. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur. J. Pharmacol. 2007, 554:69-77.
21. Hayakawa M., Miyashita H., Sakamoto I., Kitagawa M., Tanaka H., Yasuda H., Karin M., Kikugawa K. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J. 2003, 22:3356-3366.
22. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472. (New York, N.Y).
23. Kim I., Kim C.H., Kim J.H., Lee J., Choi J.J., Chen Z.A., Lee M.G., Chung K.C., Hsu C.Y., Ahn Y.S. Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis. Exp. Cell Res. 2004, 298:229-238.
24. Kim K.S., Oh da H., Choi H.M., Bang J.S., Ryu C.J., Kim J.H., Yoo M.C., Yang H.I. Pyrrolidine dithiocarbamate, a NF-kappaB inhibitor, upregulates MMP-1 and MMP-13 in IL-1beta-stimulated rheumatoid arthritis fibroblast-like synoviocytes. Eur. J. Pharmacol. 2009, 613:167-175.
25. Kitamei H., Iwabuchi K., Namba K., Yoshida K., Yanagawa Y., Kitaichi N., Kitamura M., Ohno S., Onoe K. Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate. J. Leukoc. Biol. 2006, 79:1193-1201.
26. Krenn B.M., Holzer B., Gaudernak E., Triendl A., van Kuppeveld F.J., Seipelt J. Inhibition of polyprotein processing and RNA replication of human rhinovirus by pyrrolidine dithiocarbamate involves metal ions. J. Virol. 2005, 79:13892-13899.
27. Lanke K., Krenn B.M., Melchers W.J., Seipelt J., van Kuppeveld F.J. PDTC inhibits picornavirus polyprotein processing and RNA replication by transporting zinc ions into cells. J. Gen. Virol. 2007, 88:1206-1217.
28. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., Stackhouse T., Kuzmin I., Modi W., Geil L., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320. (New York, N.Y).
29. Li Y.Q., Zhang Z.X., Xu Y.J., Ni W., Chen S.X., Yang Z., Ma D. N-Acetyl-L-cysteine and pyrrolidine dithiocarbamate inhibited nuclear factor-kappaB activation in alveolar macrophages by different mechanisms. Acta Pharmacol. Sin. 2006, 27:339-346.
30. Li H., Gu H., Sun B. Protective effects of pyrrolidine dithiocarbamate on myocardium apoptosis induced by adriamycin in rats. Int. J. Cardiol. 2007, 114:159-165.
31. Malaguarnera L., Pilastro M.R., Vicari L., Dimarco R., Manzella L., Palumbo G., Messina A. Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity. Cancer Investig. 2005, 23:404-412.
32. Mattace Raso G., Esposito E., Iacono A., Pacilio M., Coppola A., Bianco G., Diano S., Di Carlo R., Meli R. Leptin induces nitric oxide synthase type II in C6 glioma cells. Role for nuclear factor-kappaB in hormone effect. Neurosci. Lett. 2006, 396:121-126.
33. Merchionne F., Perosa F., Dammacco F. New therapies in multiple myeloma. Clin. Exp. Med. 2007, 7:83-97.
34. Montagut C., Rovira A., Albanell J. The proteasome: a novel target for anticancer therapy. Clin. Transl. Oncol. 2006, 8:313-317.
35. Moon S.K., Jung S.Y., Choi Y.H., Lee Y.C., Patterson C., Kim C.H. PDTC, metal chelating compound, induces G1 phase cell cycle arrest in vascular smooth muscle cells through inducing p21Cip1 expression: involvement of p38 mitogen activated protein kinase. J. Cell. Physiol. 2004, 198:310-323.
36. Morais C., Pat B., Gobe G., Johnson D.W., Healy H. Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol. Dial. Transplant. 2006, 21:3377-3388.
37. Nathens A.B., Bitar R., Davreux C., Bujard M., Marshall J.C., Dackiw A.P., Watson R.W., Rotstein O.D. Pyrrolidine dithiocarbamate attenuates endotoxin-induced acute lung injury. Am. J. Respir. Cell Mol. Biol. 1997, 17:608-616.
38. Nobel C.I., Kimland M., Lind B., Orrenius S., Slater A.F. Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper. J. Biol. Chem. 1995, 270:26202-26208.
39. Nobel C.S., Burgess D.H., Zhivotovsky B., Burkitt M.J., Orrenius S., Slater A.F. Mechanism of dithiocarbamate inhibition of apoptosis: thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme. Chem. Res. Toxicol. 1997, 10:636-643.
40. Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H., Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin. Exp. Rheumatol. 2005, 23:323-330.
41. Padmanabhan G., Becue I., Smith J.B. Clioquinol. Anal. Profiles Drug Subst. 1989, 18:57-90.
42. Popat R., Joel S., Oakervee H., Cavenagh J. Bortezomib for multiple myeloma. Expert Opin. Pharmacother. 2006, 7:1337-1346.
43. Rickardson L., Wickstrom M., Larsson R., Lovborg H. Image-based screening for the identification of novel proteasome inhibitors. J. Biomol. Screen. 2007, 12:203-210.
44. Ryan C.J., Wilding G. Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging 2000, 17:249-255.
45. Schreck R., Meier B., Mannel D.N., Droge W., Baeuerle P.A. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 1992, 175:1181-1194.
46. Si X., McManus B.M., Zhang J., Yuan J., Cheung C., Esfandiarei M., Suarez A., Morgan A., Luo H. Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J. Virol. 2005, 79:8014-8023.
47. Szotowski B., Antoniak S., Goldin-Lang P., Tran Q.V., Pels K., Rosenthal P., Bogdanov V.Y., Borchert H.H., Schultheiss H.P., Rauch U. Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. Cardiovasc. Res. 2007, 73:806-812.
48. Theophanides T., Anastassopoulou J. Copper and carcinogenesis. Crit. Rev. Oncol. Hematol. 2002, 42:57-64.
49. Tsai J.C., Jain M., Hsieh C.M., Lee W.S., Yoshizumi M., Patterson C., Perrella M.A., Cooke C., Wang H., Haber E., Schlegel R., Lee M.E. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J. Biol. Chem. 1996, 271:3667-3670.
50. Zavrski I., Jakob C., Kaiser M., Fleissner C., Heider U., Sezer O. Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. Recent results in cancer research. Fortschr. Krebsforsch. 2007, 176:165-176.